Welchol
(Colesevelam)ApprovedSmall molecule
Colesevelam is used to lower cholesterol levels in the blood and to help control blood sugar in people with diabetes. It works by binding to cholesterol in the digestive system so your body removes it instead of absorbing it.[2] Welchol is currently approved and in use across 5 indications[4].[1]
Welchol is one of 139 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
5
Indications
26
Total Trials
4
Active Trials
138
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Welchol
CCosette Pharmaceuticals, Inc.
Approved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric2 trials
Bile Acid Malabsorption2 trials
GLP-12 trials
Type 2 Diabetes Mellitus2 trials
Treatment2 trials
Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.
Not yet recruiting·—·Phase 1/2·NCT06197763·50 enrolled
16 more indications
Multiple Myeloma1 trial
Breast Cancer1 trial
Diarrhea1 trial
Irritable Bowel Syndrome1 trial
Gastrointestinal1 trial
Insulin Sensitivity1 trial
Magnetic Resonance Imaging1 trial
Type 2 Diabetes1 trial
Gastric Bypass Surgery1 trial
Regulatory
FDA Approval Timeline[5]
May 26, 2000
WELCHOL
NDA NDA021141
May 26, 2000
WELCHOL
NDA NDA021176
Oct 2, 2009
WELCHOL
NDA NDA022362
Apr 3, 2019
WELCHOL
NDA NDA210895
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Welchol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Colesevelam. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- CCosette Pharmaceuticals, Inc.